A SEER analysis indicates adjuvant chemotherapy for triple-negative breast cancer offers a meaningful survival benefit even for older patients—particularly those aged 70–89 with stage II–III disease—though, as always, the absolute gain varies by baseline risk. | Anampa, JAMA Netw Open 2026
